UBS downgraded Immunovant (IMVT) to Neutral from Buy with a price target of $17, down from $38.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s Strategic Developments and Growth Potential Drive Buy Rating
- Immunovant’s Strategic Advancements and Targeted Approach Drive Buy Rating
- Immunovant Announces New CEO Amid Strategic Shift
- Immunovant appoints Eric Venker as CEO, Girao as CFO
- Insider Moves: Cytokinetics, Bj’s, Gran Tierra, PBF, Immunovant